Sarepta Therapeutics Shares Drop, Prosensa Shares Rise

Shares of Sarepta Therapeutics Inc SRPT are down sharply in the premarket following an update relating to the company's drug eteplirsen.

Sarepta announced that the FDA declared the company will need to provide additional data to be included as part of the company’s NDA submission.

Following the announcement, shares of Sarepta dropped 37 percent, trading at $14.75.

On the other hand, shares of Prosensa Holding NV RNA were up 16 percent as the company is also looking to provide a drug to treat Duchenne muscular dystrophy.